NF1 G629R

CI-VAR-00001775Explore in graph →CIViC 5136

Curated evidence

Evidence by cancer (2 items)

Grouped by cancer context first, then therapy. The same variant can be sensitizing in one cancer and irrelevant in another — contexts are never merged. 50 items per page; a cancer group may continue on the next page.

civicCuratedShowing 1–2 of 2 evidence items across 1 cancer context on this page · levels, directions and significance as curated at the source; each row links to its CIViC record.

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Pilocytic Astrocytoma2
NF1 Splice Site (c.205-1G>C) AND NF1 G629R	Carboplatin + Selumetinib + Trametinib + VincristineSubstitutes	Predictive	C	Supports Sensitivity Response	2	submitted	EID12271 This study reported 47 neurofibromatosis type 1 (NF1) patients with biallelic inactivation of NF1 genes were detected in all glial tumors. Targeted capture-based next-generation sequencing (479 cancer… (full text at CIViC) PMID 35945463 · Lucas et al., 2022 · Open in CIViC	civic
NF1 Splice Site (c.205-1G>C) AND NF1 G629R	Carboplatin + Selumetinib + Trametinib + VincristineSequential	Predictive	C	Supports Sensitivity Response	2	rejected

ClinVar

Clinical significance (0)

ClinVar interpretations are shown as structured records — significance, review status, star rating, conditions — never flattened into one word.

Data not yet available

No ClinVar interpretation attached to this variant.